Latest news with #HPV-associated
Yahoo
27-03-2025
- Health
- Yahoo
Naveris Introduces Advanced NavDx+Gyn™ Test for Early Detection of HPV-Driven Gynecologic Cancers
WALTHAM, Mass., March 27, 2025--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the analytical validation of NavDx+Gyn, an important extension of the NavDx® blood test. NavDx+Gyn is a cell-free DNA-based fragmentomic profiling assay that enhances the detection and monitoring of human papillomavirus (HPV)-driven gynecologic cancers. Leveraging the robust foundation of the NavDx test, which has been validated in over 35 peer-reviewed publications and utilized in nearly 100,000 patient-physician encounters, NavDx+Gyn expands detection capabilities to include fourteen high-risk HPV types associated with cervical, vaginal, and vulvar cancers. This new blood test has been rigorously validated to provide exceptional analytical specificity and sensitivity, setting a new standard for early detection and monitoring of these cancers. The analytical validation, published in the Journal Diagnostics, confirms that NavDx+Gyn achieves outstanding limits of detection and quantitation, ensuring dependable detection of HPV types at very low concentrations. The assay's performance was extensively tested across multiple analytical metrics including accuracy, precision, and linearity, with results underscoring its high-quality standards. "NavDx+Gyn is a significant enhancement in the non-invasive surveillance of HPV-associated gynecologic cancers," said Dr. Piyush B. Gupta, PhD, Executive Chairman, Chief Science & Technology Officer, and Founder of Naveris. "Early detection is vital for effective management and treatment of these cancers." The development of NavDx+Gyn comes at a critical time, addressing the pressing need for advanced diagnostic tools in the face of the global burden of HPV-related cancers and the limitations of current diagnostic methods. By offering a reliable, non-invasive testing option, NavDx+Gyn aims to change the landscape of cancer surveillance and offer new hope to thousands of women worldwide. "Naveris is committed to advancing healthcare equity and improving outcomes for cancer patients through state-of-the-art diagnostics," added Dr. Barry M. Berger, MD, Chief Medical Officer of Naveris. "NavDx+Gyn embodies our dedication to harnessing innovation to improve patient care through early detection." Hutcheson J., Conway D., Kumar S., Wiseman C., Chakraborty S., Skrypkin E., Horan M., Gunning A., Williams C.K., Kuperwasser C., Naber S.P., and Gupta P.B. Analytical Validation of NavDx+Gyn, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Gynecologic Cancers. Diagnostics 2025, 15(7), 825. About Naveris Naveris is a privately held, commercial stage, precision oncology diagnostics company with facilities in Massachusetts and North Carolina. Since its founding in 2017, Naveris has been committed to improving outcomes for the millions of people at risk of developing viral-induced cancers with novel molecular diagnostics that enable earlier cancer detection. The company operates high-complexity testing clinical laboratories that are accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center, and are certified under CLIA. For more information on Naveris and the clinical impact of NavDx, please visit and NavDx has not been cleared or approved by the US Food and Drug Administration (FDA). View source version on Contacts Naveris Investor Relationsir@ Sign in to access your portfolio
CBC
16-02-2025
- Health
- CBC
HPV infections pose serious risks for both men and women, experts say
Gilles Charette first noticed something was going on with his body when he found an anal wart during a shower. Charette confirmed with a nurse practitioner that he had acquired a human papillomavirus (HPV) infection, and quickly received topical ointment for treatment. As a gay man in an open marriage, Charette also decided to get the HPV vaccine, choosing to pay out of pocket to be immunized rather than risk another HPV infection or HPV-associated cancer. "The recommendation was to [get vaccinated]," said Charette, who is the director of the Gay Men's Sexual Health Alliance in Toronto. "And so I did." HPV is one of the most common sexually transmitted infections in Canada and the world, and is estimated to be responsible for five per cent of all cancer cases globally. HPV infection is most commonly associated with cervical cancer, since roughly 99 per cent of all cervical cancer cases are connected to HPV. But experts warn that HPV is a virus that affects all sexually active people and can lead to a variety of cancers — regardless of gender. "We tend to focus on women because of the concern with cervix cancer … but in fact men also carry and can be infected and affected by HPV," University of British Columbia (UBC) professor Dr. Deborah Money, told Dr. Brian Goldman, host of CBC's The Dose. How common is HPV? The Public Health Agency of Canada (PHAC) estimates that roughly three quarters of sexually active men and women will have at least one HPV infection in their lifetime. "The good news is that, in fact for most people, it's a transient infection and it's cleared and it just goes away," said Money, who heads the UBC faculty of medicine's department of obstetrics and gynaecology (OBGYN). While HPV infection is dangerous for women because of the risk of cervical cancer, HPV is dangerous for gay, bisexual and other men who have sex with men because of concerns over genital and anal cancer. Of the more than 100 strains of HPV that exist in nature, two strains cause the majority of cancer cases associated with HPV, including cancers of the cervix, vagina, vulva, penis and anus. However, HPV infections can also lead to cancers of the throat, tongue and tonsils. WATCH | Calls for schools, pharmacies to boost lagging HPV vaccination rates for kids: Calls for schools, pharmacies to boost lagging HPV vaccination rates for kids 3 years ago Duration 2:02 Gilla Shapiro, a psychologist at the Princess Margaret Cancer Centre and faculty member of the Centre for Vaccine Preventable Diseases at the Dalla Lana School of Public Health, says rates of mouth and throat cancers are on the rise for men and women in Canada, but at a faster rate for men. According to numbers from the Canadian Cancer Statistics Dashboard, male head and neck cancer rates were 2.7 times higher than female head and neck cancer rates in 2019, with 2024 rates projected to be 2.8 times higher for men versus women. In communities of men who have sex with men, HIV/AIDS status is more openly discussed than whether someone has had HPV, according to Charette. bBut he notes that an HPV infection can be especially detrimental for people who are HIV positive. A 2020 review looking at the relationship between HIV status and HPV-related cancers in sub-Saharan Africa found that HIV positivity is associated with an increased prevalence of HPV infection, "which will result in increased burden of HPV-related cancers among [people living with HIV]," according to the authors. "So certainly people living with HIV should be considering HPV vaccination," said Charette. PHAC recommends that immunocompromised individuals — including people living with HIV — receive three-dose schedule of the Gardasil-9 vaccine. It estimates that 25 to 35 per cent of mouth and throat cancers are associated with oral HPV infection. The Canadian Cancer Society estimates that 90 per cent of people with anal cancer also have an HPV infection. HPV vaccines lead to reduced cancer rates, research shows Experts agree the easiest way to prevent HPV infection is through one of the two approved HPV vaccines: Gardasil-9 and Cervarix. Gardasil-9, which protects against nine types of HPV, is available for men and women, between the ages of nine and 45. Cervarix, approved for women aged nine to 45, protects against the two high-risk HPV types that cause approximately 70 per cent of all cervical cancer cases. A 2022 U.S. review found that an earlier version of Gardasil, which protected against four strains of HPV, was 90 per cent effective at reducing genital warts in males, and 77.5 per cent effective in reducing anal intraepithelial neoplasia in males, a precancerous condition that causes abnormal changes to the lining of the anal canal. According to research published by the Canadian Partnership Against Cancer, HPV immunization before the age of 17 leads to a 90 per cent reduction in invasive cervical cancer risk, while HPV immunization before the age of 30 leads to a 50 per cent reduction in cervical cancer risk. WATCH | Canada's cancer screening guidelines are out of date, doctors say: Canada's cancer screening guidelines are out of date, doctors say 10 months ago Duration 0:01 A group of cancer experts say Canadian national screening guidelines are a decade out of date, which is leading to people getting diagnosed later, when they are more difficult to treat. "They're much more effective than many of the vaccines we use," said Money. HPV vaccines are usually offered to school-aged boys and girls, ideally before the average age that they begin engaging in sexual activity. Nonetheless, even people who are already sexually active can benefit from the HPV vaccine, because the likelihood that someone has been exposed to every type of HPV that the vaccine protects against is low, according to B.C. Cancer. A Health Canada spokesperson confirmed that the National Advisory Committee on Immunization (NACI) recommends HPV vaccines for people between nine and 26 years of age. "[NACI] also recommends vaccination of individuals 27 years of age and older following a consultation with a health-care provider, in consideration of risk factors which may lead to infection with the human papilloma viruses," wrote Health Canada via email. NACI estimates that vaccine uptake for at least one dose is higher among females than males. Roughly 77 per cent of females have at least one HPV vaccine dose according to 2023 numbers, compared to 75 per cent of males. The vaccine is free for males and females under the age of 26, typically through school-based and catch-up programs in every province and territory, according to the Canadian Partnership Against Cancer. If you're older than 26 in most parts of Canada, however, you will have to pay out of pocket, like Charette. He says the price of the HPV vaccine for those not eligible for free programs — $215 per dose in Toronto, for example — can be prohibitive for some. Shapiro says there are programs developed to support the vaccination of gay, bisexual and other men who have sex with men, "because of the higher risk of developing certain types of HPV associated cancers."
Web Release
14-02-2025
- Health
- Web Release
3 ways to prevent head and neck cancer
By Editor_wr Last updated Feb 13, 2025 Throat cancer is one of the fastest-growing cancers, and it is often linked to human papillomavirus (HPV). Oropharyngeal cancer, or throat cancer, is a type of head and neck cancer that can be divided into two subgroups: HPV-associated cancers and non-HPV-associated cancers. And depending on the type of subgroup, they are treated differently. Katharine Price, M.D., a medical oncologist with the Mayo Clinic Comprehensive Cancer Center in Rochester, says there are three ways to reduce your risks and help prevent head and neck cancer. Tobacco and alcohol use increase the risk of non-HPV tumors, while HPV is responsible for about 70% of head and neck cancers. 'What's important about that is they have different biology and are much more treatable, meaning they respond better to treatments and tend to have a higher cure rate. We're sort of treating those differently than how we treat some of the non-HPV cancers,' Dr. Price says. Surgery, radiation and chemotherapy are all treatment options, but Dr. Price says it is better to reduce the risks of infection. 'The big three: no smoking tobacco use, minimizing alcohol and then HPV vaccination,' she says. 'We know that smoking and alcohol are big risk factors for head and neck cancer if you do both. This increases your risk even more,' Dr. Price says. And she encourages eating a healthy diet. 'We really should be striving to have a good whole-food diet, trying to minimize eating processed foods and refined sugars,' Dr. Price says. 3 ways to prevent head and neck cancer Prev Post Newcop Opens its First Store in Dubai with Exclusive Kicks Comments are closed.
Zawya
13-02-2025
- Health
- Zawya
3 ways to prevent head and neck cancer
DUBAI, United Arab Emirates — Throat cancer is one of the fastest-growing cancers, and it is often linked to human papillomavirus (HPV). Oropharyngeal cancer, or throat cancer, is a type of head and neck cancer that can be divided into two subgroups: HPV-associated cancers and non-HPV-associated cancers. And depending on the type of subgroup, they are treated differently. Katharine Price, M.D., a medical oncologist with the Mayo Clinic Comprehensive Cancer Center in Rochester, says there are three ways to reduce your risks and help prevent head and neck cancer. Tobacco and alcohol use increase the risk of non-HPV tumors, while HPV is responsible for about 70% of head and neck cancers. "What's important about that is they have different biology and are much more treatable, meaning they respond better to treatments and tend to have a higher cure rate. We're sort of treating those differently than how we treat some of the non-HPV cancers," Dr. Price says. Surgery, radiation and chemotherapy are all treatment options, but Dr. Price says it is better to reduce the risks of infection. "The big three: no smoking tobacco use, minimizing alcohol and then HPV vaccination," she says. "We know that smoking and alcohol are big risk factors for head and neck cancer if you do both. This increases your risk even more," Dr. Price says. And she encourages eating a healthy diet. "We really should be striving to have a good whole-food diet, trying to minimize eating processed foods and refined sugars," Dr. Price says. About Mayo Clinic Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
